Evidence map›Paper›PMID 32577505›Full record

ArticleScience advances2020

Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma.

Adriana L da Silva, Gisele P de Oliveira, Namho Kim, Fernanda F Cruz, Jamil Z Kitoko, Natalia G Blanco, Sabrina V Martini, Justin Hanes, Patricia R M Rocco, Jung Soo Suk and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. The Bioactivity ofCurrent issues in molecular biology · 2026
    Article
  3. Article
  4. Review
  5. A Spleen-Targeted Tolerogenic mRNA-LNPs Vaccine for the Treatment of Experimental Asthma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  6. Article
  7. Recent advances in nanoparticulate RNA delivery systems.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Pathologically triggeredActa pharmaceutica Sinica. B · 2023
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Adriana L da SilvaLaboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-8763-3059
Gisele P de OliveiraLaboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-6933-6341
Namho KimCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2029-8388
Fernanda F CruzLaboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0001-9443-3648
Jamil Z KitokoLaboratory of Inflammation and Immunity, Paulo de Góes Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-0973-5460
Natalia G BlancoLaboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-2818-3649
Sabrina V MartiniLaboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-0004-2828
Justin HanesCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9672-9821
Patricia R M RoccoLaboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-1412-7136
Jung Soo SukCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2437-0001
Marcelo M MoralesLaboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-3742-2050
Universidade Federal do Rio de Janeiro · BRJohns Hopkins University · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI JEFFREY MUMM · 1985 to 2026
$22.1M
New Inhalation Therapy for COPDR01HL136617 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NEPTUNE, ENID R, SUK, JUNG SOO · 2017 to 2020
$1.6M
Biodegradable Mucus Penetrating DNA Nanoparticle for Gene Therapy of CFR01HL127413 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S., SUK, JUNG SOO · 2015 to 2018
$1.6M
NEI NIH HHS P30 EY001765NHLBI NIH HHS R01 HL127413NHLBI NIH HHS R01 HL136617
6 · The paper itself

Abstract

Despite long-standing efforts to enhance care for chronic asthma, symptomatic treatments remain the only option to manage this highly prevalent and debilitating disease. We demonstrate that key pathology of allergic asthma can be almost completely resolved in a therapeutic manner by inhaled gene therapy. After the disease was fully and stably established, we treated mice intratracheally with a single dose of thymulin-expressing plasmids delivered via nanoparticles engineered to have a unique ability to penetrate the airway mucus barrier. Twenty days after the treatment, we found that all key pathologic features found in the asthmatic lung, including chronic inflammation, pulmonary fibrosis, and mechanical dysregulation, were normalized. We conducted tissue- and cell-based analyses to confirm that the therapeutic intervention was mediated comprehensively by anti-inflammatory and antifibrotic effects of the therapy. We believe that our findings open a new avenue for clinical development of therapeutically effective gene therapy for chronic asthma.

Indexed as

AsthmaNanoparticlesAnimalsDisease Models, AnimalGenetic TherapyLungMiceMice, Inbred BALB CThymic Factor, CirculatingThymic Factor, Circulating

Identifiers

PMID32577505
PMCPMC7286682
OpenAlexW3035420823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.